Hetero Ring Is Six-membered Consisting Of One Nitrogen And Five Carbon Atoms Patents (Class 514/277)
  • Patent number: 10300155
    Abstract: The present invention generally relates to various compounds that are useful as ?-synuclein ligands. The invention further relates to methods of using these compounds and their radiolabeled analogs for the detection of synucleinopathies, including Parkinson's disease (PD).
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: May 28, 2019
    Assignee: Washington University
    Inventors: Zhude Tu, Junfeng Li, Xuyi Yue, Paul Kotzbauer
  • Patent number: 10221136
    Abstract: A method of providing a cooling effect to a product includes the incorporation into the product of at least one compound of the formula I in which m is a number between 0 and 2, X, Y and Z are selected independently from the group consisting of H, halogen, OH, Me, Et, MeO and EtO, and R1, R2 and R3 together comprise at least 6 carbons, selected such that (a) (i) R1 is selected from the group consisting of H, Me, Et, isopropyl and C4-C5 branched alkyl; and ?(ii) R2 and R3 are independently selected from the group consisting of Me, Et, isopropyl and Ca-branched alkyl; or (b) any two or all of R1, R2 and R3 together form a monocyclic, bicyclic or tricyclic radical having up to 10 carbons. The compounds confer substantial cooling effects on compositions applied to the skin or taken orally, such as toothpastes, mouthwashes, foodstuffs, beverages, confectionery, tobacco products, skin creams and ointments.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: March 5, 2019
    Assignee: Givaudan, S.A.
    Inventors: Karen Ann Bell, Christophe C. Galopin, Jay Patrick Slack, Lori W. Tigani
  • Patent number: 10213395
    Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: February 26, 2019
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
  • Patent number: 10188590
    Abstract: The present invention relates to a skin-protection composition that comprises stilbenoid(s) and/or stilbenoid-containing extract(s) obtained from Dendrobium plants, such as Dendrobium officinale and Dendrobium nobile for the management of melanogenesis, skin-darkening and skin-aging. More particularly, it relates to the usage of Dendrobium ingredients and stilbenoids to reduce the formation of melanin in melanocytes. It also relates to the usage of Dendrobium ingredients and stilbenoids to reduce the generation of reactive oxygen species and oxidative free radicals. This invention relates to the use Dendrobium-derived extracts or ingredients or stilbenoids in the formulation of skin-protection, skin-whitening and/or anti-skin aging products.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: January 29, 2019
    Assignee: Hong Kong Baptist University
    Inventors: Hongjie Zhang, Siu Wai Tsang, Yu Zhu
  • Patent number: 10130267
    Abstract: A medical device system and method that includes sensing a heart sound signal from a first external sensor, determining whether a pulmonary hypertension signature is detected in response to the sensed heart sound signal, sensing a lung sound signal from a second external sensor, determining whether a heart failure signature is detected in response to the sensed lung sound signal, and determining therapy parameters in response to determining whether a pulmonary hypertension signature is detected and determining whether a heart failure signature is detected.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: November 20, 2018
    Assignee: Medtronic, Inc.
    Inventors: Zhendong Song, Xiaohong Zhou
  • Patent number: 10105405
    Abstract: A nutritional supplement composition is formulated for oral administration and enhances cognitive function. It includes huperzine A, Ginkgo biloba, and acetyl-L-carnitine. The huperzine A, acetyl-L-carnitine, and Ginkgo biloba together account for at least 80 wt % of a dosage unit of the composition. The Ginkgo biloba is about 5.0% to about 12.0%, by weight of the huperzine A, acetyl-L-carnitine and Ginkgo biloba. The Ginkgo biloba and acetyl-L-carnitine are in a ratio of y:z respectively, wherein y is between about 690 and 1,030 for Ginkgo biloba and z is between about 8,000 and 12,000 for acetyl-L-carnitine.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 23, 2018
    Assignee: KeyView Labs, Inc.
    Inventor: Josh Reynolds
  • Patent number: 9925153
    Abstract: The present invention relates to method(s) of treating a subject afflicted with a skin disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene or a stilbene hybrid. A method of treating or reducing the likelihood of a skin disease or condition in a patient is an additional embodiment of the present invention. Preferred pharmaceutical compositions of the invention include nanoemulsions comprising a therapeutically effective amount of a substituted cis or trans-stilbene or stilbene hybrid and at least one antibiotic.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: March 27, 2018
    Assignee: STC.UNM
    Inventors: David L Vander Jagt, Lorraine M Deck, Robert E Royer, John E Heidrich
  • Patent number: 9867789
    Abstract: The use of a non-steroidal anti-inflammatory drug for the treatment of nonproductive cough caused by viruses or bacteria and a combination of at least one non-steroidal anti-inflammatory drug with at least one antitussive in a formulation to treat coughs.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: January 16, 2018
    Assignee: BAYER CONSUMER CARE AG
    Inventors: Marianne Petersen-Braun, Chirin Yekrangi-Hartmann, Uwe Gessner, Michael Völker
  • Patent number: 9832992
    Abstract: A synergistic microbicidal composition having two components. The first component is a nonionic surfactant with structure: R2O(CH2CH(CH3)O)3(CH2CH2O)5H, where R2 is a mixture of C8-C14 linear alkyl groups. The second component is 2-bromo-2-nitropropane-1,3-diol. The weight ratio of the nonionic surfactant to 2-bromo-2-nitropropane-1,3-diol is from 1:0.08 to 1:0.12 or 1:0.2 to 1:1.8286.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: December 5, 2017
    Assignees: Dow Global Technologies LLC, Rohm and Haas Company
    Inventors: Usha Gandhi, Christine McInnis, Kiran Pareek, Paul O. Schook, Nigel G. Watson, Terry Michael Williams, Bei Yin
  • Patent number: 9796673
    Abstract: The subject invention provides pridopidine L-tartrate, compositions and a process for manufacture thereof.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: October 24, 2017
    Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
    Inventors: Raeann Wu, Ralph Curtis Haltiwanger, Stephen Bierlmaier, Mehran Yazdanian
  • Patent number: 9737519
    Abstract: Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Remarkably, clinical studies have proven that contemplated compositions achieved the desired effects using a minimal number of active ingredients at or near threshold active dosages, wherein such compositions almost exclusively comprise huperzine A, vinpocetine or rhodiola, and acetyl-L-carnitine, and optionally further include alpha lipoic acid, rhodiola, and biotin.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: August 22, 2017
    Assignee: KeyView Labs, Inc.
    Inventor: Josh Reynolds
  • Patent number: 9737580
    Abstract: A nutritional supplement composition enhances cognitive function and includes huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola. The composition is formulated for oral administration. The huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola are in a ratio a:b:c:d: respectively such that a as the huperzine A is between about 0.8 and 1.2, b as vinpocetine is between about 80 and 120, c as rhodiola is about 1,600 and 2,400, and d as the acetyl-L-carnitine is between about 8,000 and 12,000.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: August 22, 2017
    Assignee: KeyView Labs, Inc.
    Inventor: Josh Reynolds
  • Patent number: 9713597
    Abstract: An aqueous pharmaceutical solution composition comprising between about 20 mg/ml to about 100 mg/ml of a radioprotective ?,?-unsaturated aryl sulfone, a cosolvent comprising polyethylene glycol (PEG), polypropylene glycol, polyglycerol, DMA, propylene glycol, glycerol, ethanol, sorbitol, isopropyl alcohol, or a combination thereof in an amount between about 25% and about 90% w/v, and a water soluble Vitamin E derivative, wherein the composition has a pH within the range of about 7.0 to about 9.5.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: July 25, 2017
    Assignee: ONCONOVA THERAPEUTICS, INC.
    Inventor: Manoj Maniar
  • Patent number: 9682073
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: June 20, 2017
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Patent number: 9682910
    Abstract: The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: June 20, 2017
    Assignee: Unigen, Inc.
    Inventors: Sandip K. Nandy, Jiyun Liu, Alexandre Mikhailovitch Nesterov, Carmen Hertel, Abeysinghe Arrachchigae Papmapiya
  • Patent number: 9622993
    Abstract: Lysophosphatidic acid acyltransferase-beta (LPAAT-?) catalyzes the production of phosphatidic acid (PA) from lysophosphatidic acid (LPA). The lipid cofactor PA contributes to the activation of c-Raf, BRAF, mTOR and PKC-?. LPAAT-? expression is a prognostic factor in gynecologic malignancies and is being investigated as a therapeutic target in a variety of tumor types. A class of thiosemicarbazones was identified as inhibitors of LPAAT-? from a screen of a library of small molecules. A focused library of thiosemicarbazones derivatives was prepared and led to the development of compounds which potently inhibit LPAAT-? and inhibit the growth of MiaPaCa2 human pancreatic cancer cells.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: April 18, 2017
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Gregory Springett, Said M. Sebti, Nicholas J. Lawrence
  • Patent number: 9603884
    Abstract: A nutritional supplement composition enhances cognitive function and includes huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola. The composition is formulated for oral administration. The huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola are in a ratio a:b:c:d: respectively such that a as the huperzine A is between about 0.8 and 1.2, b as vinpocetine is between about 80 and 120, c as rhodiola is about 1,600 and 2,400, and d as the acetyl-L-carnitine is between about 8,000 and 12,000.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: March 28, 2017
    Assignee: KeyView Labs, Inc.
    Inventor: Josh Reynolds
  • Patent number: 9522934
    Abstract: Provided are acetaic abiraterone trifluoroacetate, a preparation method and an application of same. The acetaic abiraterone trifluoroacetate is obtained through a salt-forming reaction between acetaic Abiraterone and trifluoroacetic acid. The acetaic abiraterone trifluoroacetate undergoes self-purification through recrystallization, and dissociation and recrystallization are performed on the purified abiraterone acetate trifluoroacetate, so that the obtained acetaic abiraterone has a high purity, a high yield and stable quality, and is capable of meeting the requirement for mass production of acetaic abiraterone.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: December 20, 2016
    Assignees: Shanghai Cdymax Pharmaceuticals Co., Ltd., Jiangsu Cdymax Pharmaceuticals Co., Ltd., Shanghai Acebright Pharmaceuticals Group Co., Ltd.
    Inventors: Xiaoxia An, Chengjun Huang, Fengwang Mao
  • Patent number: 9408838
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment and a speech impairment secondary to a non degenerative disease or disorder acquired in utero, at birth or in infancy, but later manifested.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: August 9, 2016
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Patent number: 9381193
    Abstract: The invention encompasses compositions and methods for use in preventing pregnancy.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: July 5, 2016
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Kelle H. Moley, Antonina I. Frolova
  • Patent number: 9375402
    Abstract: The invention is directed to formulations of bioactive compounds of limited water solubility, inhibitors of focal adhesion kinase (FAK) of the 2,4-diaminopyridine class, adapted for oral administration to patients. The formulations are self-emulsifying in the gastrointestinal tract of the patients, providing enhanced absorption and bioavailability of the bioactive compounds as dispersions or emulsions in an oil base. For example, esters of PEG-ylated glycerol can be used as the oil, in conjunction with surfactants such as lecithin and TEPG succinate and solubilizers such as PEG 400 to provide useful oral formulations for administration to patients having a malcondition wherein inhibition of FAK is medically indicated, such as cancer or arthritis.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: June 28, 2016
    Assignee: VERASTEM, INC.
    Inventors: Andrew Xian Chen, Yali J. Tsai
  • Patent number: 9359298
    Abstract: Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: June 7, 2016
    Assignee: INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Zhuorong Li, Xingyue Ji, Situ Xue, Guanghui Zheng, Yuhuan Li, Peizhen Tao, Jiandong Jiang
  • Patent number: 9333198
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment secondary to cerebral palsy, or a gait impairment resultant side effect from anti-cancer and anti-seizure drugs. The administered methylphenidate simultaneously treats speech and gait or limb impairments secondary to a disease or disorder.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: May 10, 2016
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Patent number: 9327002
    Abstract: Compositions and methods are provided that enhance cognition in a human to which the composition is orally administered. Remarkably, clinical studies have proven that contemplated compositions achieved the desired effects using a minimal number of active ingredients at or near threshold active dosages, wherein such compositions almost exclusively comprise huperzine A, vinpocetine or rhodiola, and acetyl-L-carnitine, and optionally further include alpha lipoic acid, rhodiola, and biotin.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: May 3, 2016
    Assignee: KeyView Labs, Inc.
    Inventor: Josh Reynolds
  • Patent number: 9314474
    Abstract: The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: April 19, 2016
    Assignee: HYBRIGENICS, SA
    Inventor: Remi Delansorne
  • Patent number: 9308232
    Abstract: A nutritional supplement composition enhances cognitive function and includes huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola. The composition is formulated for oral administration. The huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola are in a ratio a:b:c:d: respectively such that a as the huperzine A is between about 0.8 and 1.2, b as vinpocetine is between about 80 and 120, c as rhodiola is about 1,600 and 2,400, and d as the acetyl-L-carnitine is between about 8,000 and 12,000.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: April 12, 2016
    Assignee: KeyView Labs, Inc.
    Inventor: Josh Reynolds
  • Patent number: 9307942
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment secondary to cerebral palsy, or a gait impairment resultant side effect from anti-cancer and anti-seizure drugs. The administered methylphenidate simultaneously treats speech and gait or limb impairments secondary to a disease or disorder.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: April 12, 2016
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Patent number: 9296702
    Abstract: The invention discloses a method for the treatment of diseases, particularly those diseases characterized by diminished or aberrant cellular function, including AIDS, cancer, and Alzheimer's Disease. The method comprises administering a therapeutically effective amount of rosuvastatin enantiomer compounds in their (3R, 5R), (3S, 5R), or (3S, 5S) configurations, or pharmaceutically acceptable salts thereof. Biologically-active rosuvastatin enantiomer compounds with (3R, 5R), (3S, 5R), and (3S, 5S) stereochemistry are also disclosed.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: March 29, 2016
    Inventor: Terence J. Scallen
  • Patent number: 9278096
    Abstract: New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: March 8, 2016
    Assignees: H. Lundbeck A/S, Takeda Pharmaceuticals North America, Inc.
    Inventor: Marianne Dragheim
  • Patent number: 9254282
    Abstract: The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: February 9, 2016
    Assignee: COLD SPRING HARBOR LABORATORY
    Inventors: Timothy P. Tully, Filippo Cavalieri, Rusiko Bourtchouladze
  • Patent number: 9241925
    Abstract: The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: January 26, 2016
    Assignee: Dart NeuroScience LLC
    Inventors: Timothy P. Tully, Filippo Cavalieri, Rusiko Bourtchouladze
  • Patent number: 9220712
    Abstract: A pharmaceutical intervention and therapeutic method for treating an apraxia of speech in children. The child can also be diagnosed with gait abnormalities or impairment autism, mental retardation and dyslexia. If the child demonstrates at least an 18 to 24 month development stage of either verbal development or non-verbal development, a therapeutic dose of a dopamine agonistic, particularly a nonlinear lower alkyl phenidate or dextro-threo-methylphenidate is administered to the child.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: December 29, 2015
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Patent number: 9216148
    Abstract: Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPAR? and PPAR? activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: December 22, 2015
    Assignee: Pusan National University Industry-University Cooperation Foundation
    Inventors: Hae Young Chung, Hyung Ryong Moon, Min Hi Park, Young Mi Ha, Yun Jung Park, Ji Young Park, Jin Ah Kim, Ji Yeon Lee, Kyung Jin Lee
  • Patent number: 9199976
    Abstract: The present invention generally relates to compounds that inhibit haematopoietic-prostaglandin D2 synthase (H-PGDS), to compositions containing them and to their use in treating or preventing conditions and diseases associated with H-PGDS, such as allergies and inflammation.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: December 1, 2015
    Assignee: The University of Queensland
    Inventors: Mark Leslie Smythe, Jack Urquhart Flanagan
  • Patent number: 9161718
    Abstract: Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: October 20, 2015
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Patent number: 9155502
    Abstract: Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: October 13, 2015
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Patent number: 9149468
    Abstract: The invention relates to novel multicomponent crystals, to the production thereof, and to the use thereof for treating pain conditions, in particular of unclear genesis, by means of a simultaneous effect on pains which are caused by muscle tension or degenerative joint diseases as well as on pains that are based on inflammatory processes. The novel multicomponent crystals contain ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester (flupirtine) and 2-[2-[(2,6-dichlorphenyl)-amino]-phenyl]-acetic acid (diclofenac) as the sole active ingredient combination and can be produced by dissolving the two components in a molar ratio of 1.0:0.9 to 1.0:1.1 in an inert organic solvent and subsequently crystallizing the complex compound.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: October 6, 2015
    Assignee: TEVA GmbH
    Inventors: Christoph Martin Hoock, Asal Qadan, Bernd Terhaag
  • Patent number: 9089563
    Abstract: A therapeutic method for treating apraxia of speech in children. The child can also be diagnosed with autism, mental retardation, dyslexia. Verbal development stages and nonverbal development stages are tested and observed. If a child demonstrates at least 18 to 24 month development stage of either the verbal development or the non-verbal development, a therapeutic dosage of dopamine agonistic medicine is administered to the child in addition to speech therapy and language training.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: July 28, 2015
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventor: Bruce Roseman
  • Patent number: 9066938
    Abstract: The present invention provides compositions including anti-tumor agents and inhibitors of Goodpasture antigen binding protein, p21, and ABCC7, and their use in treating cancer.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: June 30, 2015
    Assignees: Fibrostein, S.L., Universitat de Valencia
    Inventors: Juan Saus, Francisco Revert-Ros, Fernando Revert, Carmen Aguado-Velasco, Ernesto López-Pascual, Alejandra María Pérez-Sastre, Raúl Blasco, Héctor Pérez-Montoyo
  • Patent number: 9051296
    Abstract: The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar1 is phenyl; Ar2 is aryl; n is 1-4; X is —O—, —S—, —SO— or —SO2—, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of such disorders and diseases as pain in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases as pain in which voltage gated sodium channels are involved.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: June 9, 2015
    Assignee: RaQualia Pharma Inc.
    Inventors: Tatsuya Yamagishi, Yoshimasa Arano, Mikio Morita, Tadashi Inoue
  • Publication number: 20150148362
    Abstract: The present invention relates to a pharmaceutical composition or a functional health food comprising a verbenone derivative and pharmaceutically acceptable salts thereof as active ingredients for treating or preventing a neurodegenerative disease. More specifically, the verbenone derivative according to the present invention reduces neuronal cell death and oxidative stress, and is highly effective in preventing ischemic brain damage and inflammatory cell migration in rats, thereby providing the pharmaceutical composition or the functional health food which is useful in treating neurodegenerative diseases.
    Type: Application
    Filed: June 4, 2013
    Publication date: May 28, 2015
    Inventors: Won Ki Kim, Yongseok Choi, Sumi Song
  • Patent number: 9040538
    Abstract: The present invention features compounds having the Formula (Ia) and (Ib) (e.g., a compound of any of Formulas ((Ia-2)-(Ia-21)), including other tautomers, stereoisomers, E/Z stereoisomers, prodrugs, pharmaceutically acceptable salts, and compositions thereof. The invention also features methods for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient by administering an effective amount of a compound of Formula (Ia) or (Ib). The invention also features a method for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient that includes administering to a patient in need thereof an effective amount of a compound of Formula (IIa) or (IIb) (e.g., a compound of any of Formulas ((IIa-2)-(IIa-6)). The compounds described herein (e.g., a compound of Formulas (Ia), (Ib), (IIa), or (IIb)) can also be used as anticonvulsants.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: May 26, 2015
    Assignee: Universite Laval
    Inventors: Giorgio Attardo, Sasmita Tripathy, Martin Gagnon
  • Publication number: 20150141471
    Abstract: The present invention relates to compounds of the formula (I), wherein the residues R1 to R6, V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses. The compounds of the invention are effective antagonists of the platelet LPA receptor LPAR5 (GPR92) and can in general be applied in conditions in which an undesired activation of the platelet LPA receptor LPAR5, the mast cell LPA receptor LPAR5 or the microglia cell LPA receptor LPAR5 is present, or for the cure or prevention of which an inhibition of the platelet, mast cell or microglia cell LPA receptor LPAR5 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: May 16, 2013
    Publication date: May 21, 2015
    Inventors: Marc Nazare, Detlef Kozian, Andreas Evers, Werngard Czechtizky
  • Publication number: 20150141380
    Abstract: A method of treating a subject at risk of or suspected of having Fragile X syndrome or autism spectrum disorder associated with abnormalities of ERK includes administering to the subject a therapeutically effective amount of at least one ERK inhibiting compound that prevents abnormalities in neuronal connectivity, a prodrug thereof that is metabolisable to form the compound, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 5, 2011
    Publication date: May 21, 2015
    Applicant: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Mark A. Smith, Michael Snape
  • Publication number: 20150140061
    Abstract: Stents with coatings comprising a combination of a restenosis inhibitor comprising an HMG-CoA reductase inhibitor and a carrier. Also provided are methods of coating stents with a combination of an HMG-CoA reductase inhibitor and a carrier. A preferred example of a restenosis inhibitor is cerivastatin. The stent coatings have been shown to release restenosis inhibitors in their active forms.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 21, 2015
    Inventor: Chandrashekhar Pathak
  • Patent number: 9029413
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, and in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. Antiviral activity of enzyme inhibitors is demonstrated.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: May 12, 2015
    Assignee: The Trustees of Princeton University
    Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
  • Patent number: 9028854
    Abstract: A pesticidal composition comprising 4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether; a hydrophobic organic solvent capable of dissolving 0.1-fold by weight of 4-phenoxyphenyl 2-(2-pyridyloxy)propyl ether at 0° C.; polyvinyl alcohol; a nonionic surfactant selected from the group consisting of alkoxylated castor oil, alkoxylated hydrogenated castor oil and alkoxylated hydrogenated castor oil fatty acid ester; and water, is excellent in storage stability.
    Type: Grant
    Filed: December 13, 2005
    Date of Patent: May 12, 2015
    Assignee: Sumitomo Chemical Company, Limited
    Inventor: Toshiyuki Tanedani
  • Patent number: 9029386
    Abstract: Derivatives of pyridine of the formula wherein one of Y and A is CR and the other is N are kinase inhibitors useful in treating conditions associated with excess kinase activity.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: May 12, 2015
    Assignee: Gilead Sciences, Inc.
    Inventors: Christopher John Burns, Michael Francis Harte, James T. Palmer
  • Patent number: 9023874
    Abstract: The invention relates to alkylsulfide derivatives compounds of formula I as hereunder depicted or the enantiomers or veterinarily acceptable salts thereof which are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to methods for controlling invertebrate pests by using these compounds and to plant propagation material and to agricultural and veterinary compositions comprising said compounds. wherein U, R1, R2, R3U, X, n and p are defined as in the description.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: May 5, 2015
    Assignee: Merial, Inc.
    Inventors: Sebastian Soergel, Ralph Paulini, Steffen Gross, Carsten Beyer, Matthias Pohlman, Henricus Maria Martinus Bastiaans, Michael Rack, Deborah L. Culbertson, Douglas D. Anspaugh, Sarah Thompson, Vincent Salgado
  • Publication number: 20150119414
    Abstract: A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.
    Type: Application
    Filed: January 2, 2015
    Publication date: April 30, 2015
    Applicant: PIVOTAL THERAPEUTICS INC.
    Inventors: George JACKOWSKI, Rachelle MACSWEENEY, Nisar Ahmad SHAIKH, Jason YANTHA, Valerie B. SCHINI-KERTH